Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link Emerging incretin and multi agonist based treatments the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio kidney liver metabolic diseases and beyond Metabolism Clinical and Experimental Incretin based therapies for the treatment of obesity related diseases npj Metabolic Health and Disease Once weekly mazdutide, a glucagon like peptide 1 and glucagon receptor dual agonist, provided clinically relevant reduction in body weight in Chinese adults with obesity or overweight. Full GLORY 1 trial results: https: nej.md 4koUvaP Forest plot of the effect of Mazdutide vs Placebo on the percentage of Download Scientific Diagram Mazdutide 10mg Loti Labs